Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per share, including the exercise in full by the underwriters of their option to purchase up to 2,400,000 additional shares of common stock. The offering raised gross proceeds of approximately $46 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Cowen and Cantor Fitzgerald & Co. acted as lead book-running managers for the offering. SunTrust Robinson Humphrey acted as a bookrunner for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering. H.C. Wainwright & Co. acted as co-manager for the offering.

Marinus intends to use the net proceeds of the offering to fund the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments.

The shares of common stock described above were offered by the Company pursuant to a registration statement on Form S-3 (No. 333-221243) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on December 1, 2017. A preliminary prospectus supplement related to the public offering was filed with the SEC on May 28, 2020. A final prospectus supplement relating to the public offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by telephone at [phone], or by email at [e-mail], or Cantor Fitzgerald & Co., 499 Park Avenue, 6th Floor, New York, New York 10022, Attn: Capital Markets Department, or by email at [e-mail].